Literature DB >> 21224325

Ensuring safe and effective drugs: who can do what it takes?

Tom Jefferson1, Peter Doshi, Matthew Thompson, Carl Heneghan.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21224325     DOI: 10.1136/bmj.c7258

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  15 in total

1.  [Evidence-based anesthesiology: knowledge transfer from research into clinical practice].

Authors:  H R Grobe; F Kunath; M R Tramèr; B Lang; J J Meerpohl
Journal:  Anaesthesist       Date:  2011-05       Impact factor: 1.041

2.  Does oseltamivir really reduce complications of influenza?

Authors: 
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

3.  The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Authors:  Peter Doshi; Tom Jefferson; Chris Del Mar
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

4.  How can we improve the interpretation of systematic reviews?

Authors:  Andrea C Tricco; Sharon E Straus; David Moher
Journal:  BMC Med       Date:  2011-03-30       Impact factor: 8.775

5.  Why we need easy access to all data from all clinical trials and how to accomplish it.

Authors:  Peter C Gøtzsche
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279

Review 6.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

Review 7.  Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Elizabeth A Spencer; Igho Onakpoya; Carl J Heneghan
Journal:  BMJ       Date:  2014-04-09

8.  Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports.

Authors:  Peter Doshi; Tom Jefferson
Journal:  BMJ Open       Date:  2013-02-26       Impact factor: 2.692

Review 9.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

Review 10.  Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.

Authors:  Emma Maund; Britta Tendal; Asbjørn Hróbjartsson; Karsten Juhl Jørgensen; Andreas Lundh; Jeppe Schroll; Peter C Gøtzsche
Journal:  BMJ       Date:  2014-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.